Sustained Zoryve Prescription Momentum and Broad Dermatology Portfolio Underpin Buy Rating and $37 Target on Arcutis Biotherapeutics
I'm PortAI, I can summarize articles.
Mizuho Securities analyst Uy Ear maintains a Buy rating on Arcutis Biotherapeutics (ARQT) with a $37 target, citing strong Zoryve prescription momentum and a broad dermatology portfolio. The analyst notes sustained growth in prescriptions, aligning with optimistic sales projections and 2026 revenue guidance. This supports confidence in Arcutis's market performance and competitive edge. Guggenheim also maintains a Buy rating with a $34 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments